GLP 1 inflammatory bowel disease data come almost entirely from records studies

Interest in GLP 1 inflammatory bowel disease research is growing because more people with Crohn's disease or ulcerative colitis also live with obesity or type 2 diabetes. A new explainer from News Medical walks through the evidence, and its main source, a systematic review in Alimentary Pharmacology and Therapeutics, shows how thin that evidence still is. Of 14 studies that met the review's criteria, 13 looked back at existing records. None assigned patients to treatment at random.

Why gut doctors are asking

Inflammatory bowel disease, the umbrella term for Crohn's disease and ulcerative colitis, was long thought of as a wasting illness. That picture has changed. The review, by Maracle and colleagues at the University of Calgary, cites cohorts in which 15% to 40% of adults with the condition have obesity and another 20% to 40% are overweight. Metabolic syndrome is estimated at nearly 20% overall, higher in ulcerative colitis than in Crohn's disease, and diabetes affects about 5% of patients in large cohorts. These overlaps make many people with IBD candidates for GLP 1 receptor agonists, the peptide drugs used for diabetes and weight loss. Yet people with IBD were largely left out of the pivotal trials of these drugs.

Doctors have two separate questions. The first is safety. GLP 1 drugs slow the stomach and often cause nausea, vomiting, diarrhoea or constipation, symptoms that can be hard to tell apart from a flare and could, in principle, worsen nutrition in people who already struggle to eat enough. The second is whether the drugs might do more than help with weight. Laboratory work suggests GLP 1 receptors sit on some immune cells in the gut lining, and in mouse colitis models liraglutide reduced weight loss and tissue inflammation scores. News Medical notes that another animal model hinted at a risk, more bacteria crossing the gut wall, so the animal data do not point in only one direction.

What the review found

The authors describe their work as the most comprehensive look so far at GLP 1 inflammatory bowel disease data. They searched four databases up to 9 September 2025 and screened more than 7,000 records. Fourteen studies qualified, 13 retrospective cohorts and one case control study, with ten from the United States, two from Denmark and one each from Spain and Israel. They ranged from 16 to 61,927 participants and followed people for three months to seven years. All ten studies that reported weight showed a fall in weight or body mass index. Because designs, comparison groups and outcome measures varied so much, the authors did not pool the results into a single estimate.

All ten studies that reported weight showed a fall in weight or body mass index.

The disease outcomes are where the interest lies. In an Israeli national cohort of people with IBD and type 2 diabetes, GLP 1 users had a lower risk of steroid dependence, with a hazard ratio of 0.66, and of hospital admission, at 0.74, compared with non users. A Danish registry of 3,751 patients found lower rates of steroid use, and a rate ratio of 0.52 for a composite of anti TNF treatment, hospital admission or surgery, among people taking GLP 1 drugs or the related DPP 4 inhibitors. Across the data sets, the review found no sign that GLP 1 drugs made IBD flare more often, and side effects were mostly gastrointestinal, much as in people without IBD.

The evidence in one table

The pattern is consistent, but consistency across records studies is not the same as proof. People who are offered a GLP 1 drug may differ from those who are not in ways the records do not capture, such as access to specialist care, how active their bowel disease is, or how closely they are followed. The review notes that most cohorts involved relatively mild disease, that endoscopy and tissue samples were rarely used to measure inflammation, and that billing codes and prescription changes are rough stand ins for disease activity. Some studies compared patients with themselves before and after starting the drug, which cannot separate drug effects from the natural ups and downs of IBD.

There are also open safety questions specific to IBD. News Medical highlights a single case report in which starting tirzepatide was followed by higher levels of thiopurine breakdown products and abnormal liver tests, a possible sign that slower stomach emptying alters how other medicines behave. One case cannot show how often this happens. Gallstones and gallbladder inflammation, known risks of the drug class, still apply. Evidence is especially sparse for people with severe, stricturing or treatment resistant disease, and for the effect on muscle mass in patients who may be both overweight and undernourished. The authors call for prospective studies built for IBD, using endoscopy and biomarkers rather than codes. Related trials are covered in our clinic section.

Reading GLP 1 inflammatory bowel disease claims with care

The most cautious reading is that GLP 1 drugs seem to be tolerated about as well in people with IBD as in other patients and help them lose weight, while the hint of fewer steroid courses, admissions and operations remains a hypothesis. It is not clear whether any benefit would come from a direct effect on gut inflammation, from weight loss and better blood sugar, or simply from differences between the people who receive these drugs and those who do not. News Medical makes the same point. An Israeli subgroup analysis cited in the explainer found no clear benefit in people without obesity, which fits the idea that metabolic change, rather than an anti inflammatory action, drives much of the signal.

For patients, the evidence does not support using these drugs to treat bowel inflammation itself, and decisions about IBD treatment remain a matter for a gastroenterologist. Researchers have a clearer list of tasks: prospective or randomised studies in IBD, measures of mucosal healing, and follow up long enough to see whether any early signal on admissions and surgery holds. Until then, results from animals and registries should be read as reasons to test the idea, not as evidence that GLP 1 drugs treat Crohn's disease or ulcerative colitis. The review itself is open access on PMC. Key numbers from studies like it go on our figures page.

Conclusion

The GLP 1 inflammatory bowel disease evidence is growing quickly but remains observational. Fourteen studies, nearly all based on records, point to weight loss, acceptable tolerance and possibly fewer steroid courses and admissions. None was randomised, most involved milder disease, and the reasons behind the associations are unknown. The next step is a prospective trial designed for people with IBD.

Source Maracle B, Quan S, Hamilton P and colleagues. Systematic Review: Efficacy, Safety and Metabolic Outcomes of GLP-1 Receptor Agonists in Inflammatory Bowel Disease. Alimentary Pharmacology and Therapeutics, 2025. DOI 10.1111/apt.70485

Amino Weekly reports research. It is not medical advice and never gives doses.